ArticleCancers2023
Evaluation of CIN2/3 Lesion Regression in GynTect
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Methylation biomarkers in non-regressive cervical intraepithelial neoplasia grade 2 lesions: an epigenome wide association study.British journal of cancer · 2026Article
- DNA Methylation in Cervical Intraepithelial Neoplasia and Cervical Cancer: Triage and Management.Current topics in microbiology and immunology · 2026Review
- Epigenetic Biomarkers for Cervical Cancer Progression: A Scoping Review.International journal of molecular sciences · 2025Article
- The DNA Methylation MarkerCancers · 2025Article
- Novel triple-target panels utilizing methylation-sensitive restriction enzyme-based quantitative PCR for detecting advanced cervical precancers and cancers among high-risk HPV-positive women.Journal of translational medicine · 2025Article
- Biomarkers differentiating regression from progression among untreated cervical intraepithelial neoplasia grade 2 lesions.Journal of advanced research · 2025Review
- Article
- DNA methylation signatures of cervical pre-invasive and invasive disease: An epigenome-wide association study.International journal of cancer · 2025Article
- Performance of a six-methylation-marker assay in predicting LEEP specimen histology results of cervical HSIL patients: a retrospective study.BMC cancer · 2025Article
- Comparative evaluation of two DNA methylation assays for triage of hrHPV E6/E7 mRNA-positive women.Frontiers in public health · 2025Article
- Accuracy of GynTectCancers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 1 country.
Funding
Abstract
Cervical intraepithelial neoplasia (CIN) grade 2/3 has a high spontaneous regression rate, especially among women ≤29 years of age. To reduce overtreatment, reliable prognostic biomarkers would be helpful. The main aim of this study was to analyze the negative predictive value of the methylation marker panel GynTect
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.